Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery with Low Ejection Fraction | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 113, Volume 99, Issue 1, April 2025, Pages 2161-2168 PDF (322.42 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2025.430874 | ||
| Abstract | ||
| Background: Levosimendan is regarded as the best inotropic substance to promote heart health. It has a lusitropic effect and increases cardiac output with a little increase in myocardial oxygen consumption due to its pharmacodynamics. Objective: Levosimendan impact on patients undergoing coronary artery bypass surgery alone, valve alone and combined surgery with low ejection fraction less than 35%. Patients and Method: Retrospective randomized study done at Cardiothoracic Surgery Department, Zagazig University, Egypt, January 2021 - October 2024. Each group of the three main groups was subdivided in to two groups; levosimendan group and traditional inotropes group. Results: Levosimendan in coronary artery bypass grafting (CABG) alone, combined, valve alone: had statistically significant difference in some variables of primary outcomes and secondary outcomes, but in valve alone: significant difference in some variables of secondary outcomes and single variable of primary outcomes, however hypotension and atrial fibrillation showed significant difference in the all studied groups Conclusion: Levosimendan has many positive outcomes post cardiac surgery in patients with low ejection fraction. Differential effect based on pathophysiology mechanisms more obviously on ischemic rather than pressure or volume cardiomyopathy. | ||
| Keywords | ||
| Levosimendan; Cardiac surgery; Low ejection fraction | ||
|
Statistics Article View: 130 PDF Download: 84 |
||
